Ipsen’s Palovarotene Hit By FDA Clinical Hold

Analysts Cut Their Palovarotene Sales Projections

 
• By Sten Stovall
  
Stop
Palovarotene is Ipsen’s lead pipeline asset for treating two rare bone diseases • Source: Shutterstock

More from Clinical Trials

More from R&D